| BET bromodomain inhibition as a therapeutic strategy to target c-Myc JE Delmore, GC Issa, ME Lemieux, PB Rahl, J Shi, HM Jacobs, E Kastritis, ... Cell 146 (6), 904-917, 2011 | 3116 | 2011 |
| The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins G Lu, RE Middleton, H Sun, MV Naniong, CJ Ott, CS Mitsiades, KK Wong, ... Science 343 (6168), 305-309, 2014 | 1484 | 2014 |
| NF-κB as a therapeutic target in multiple myeloma T Hideshima, D Chauhan, P Richardson, C Mitsiades, N Mitsiades, ... Journal of Biological Chemistry 277 (19), 16639-16647, 2002 | 1181 | 2002 |
| Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets T Hideshima, C Mitsiades, G Tonon, PG Richardson, KC Anderson Nature Reviews Cancer 7 (8), 585-598, 2007 | 1172 | 2007 |
| Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma PG Richardson, RL Schlossman, E Weller, T Hideshima, C Mitsiades, ... Blood, The Journal of the American Society of Hematology 100 (9), 3063-3067, 2002 | 1053 | 2002 |
| Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma PG Richardson, E Weller, S Lonial, AJ Jakubowiak, S Jagannath, ... Blood, The Journal of the American Society of Hematology 116 (5), 679-686, 2010 | 1045 | 2010 |
| Molecular sequelae of proteasome inhibition in human multiple myeloma cells N Mitsiades, CS Mitsiades, V Poulaki, D Chauhan, G Fanourakis, X Gu, ... Proceedings of the National Academy of Sciences 99 (22), 14374-14379, 2002 | 937 | 2002 |
| The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications N Mitsiades, CS Mitsiades, PG Richardson, V Poulaki, YT Tai, D Chauhan, ... Blood, The Journal of the American Society of Hematology 101 (6), 2377-2380, 2003 | 936 | 2003 |
| The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. N Mitsiades, CS Mitsiades, PG Richardson, V Poulaki, G Fanourakis, ... Blood 100 (11), 105A-106A, 2002 | 936 | 2002 |
| Targeting transcription regulation in cancer with a covalent CDK7 inhibitor N Kwiatkowski, T Zhang, PB Rahl, BJ Abraham, J Reddy, SB Ficarro, ... Nature 511 (7511), 616-620, 2014 | 843 | 2014 |
| A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib D Chauhan, L Catley, G Li, K Podar, T Hideshima, M Velankar, ... Cancer cell 8 (5), 407-419, 2005 | 840 | 2005 |
| Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications N Mitsiades, CS Mitsiades, V Poulaki, D Chauhan, PG Richardson, ... Blood, The Journal of the American Society of Hematology 99 (12), 4525-4530, 2002 | 833 | 2002 |
| Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors CS Mitsiades, NS Mitsiades, CJ McMullan, V Poulaki, R Shringarpure, ... Cancer cell 5 (3), 221-230, 2004 | 792 | 2004 |
| Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341 T Hideshima, C Mitsiades, M Akiyama, T Hayashi, D Chauhan, ... Blood, The Journal of the American Society of Hematology 101 (4), 1530-1534, 2003 | 752 | 2003 |
| Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341. T Hideshima, C Mitsiades, M Akiyama, T Hayashi, D Chauhan, ... Blood 100 (11), 814A-814A, 2002 | 752 | 2002 |
| Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications CS Mitsiades, NS Mitsiades, CJ McMullan, V Poulaki, R Shringarpure, ... Proceedings of the National Academy of Sciences 101 (2), 540-545, 2004 | 676 | 2004 |
| A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma PG Richardson, E Blood, CS Mitsiades, S Jagannath, SR Zeldenrust, ... Blood 108 (10), 3458-3464, 2006 | 654 | 2006 |
| Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy TN Chonghaile, KA Sarosiek, TT Vo, JA Ryan, A Tammareddi, ... Science 334 (6059), 1129-1133, 2011 | 641 | 2011 |
| Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model R LeBlanc, LP Catley, T Hideshima, S Lentzsch, CS Mitsiades, ... Cancer research 62 (17), 4996-5000, 2002 | 633 | 2002 |
| Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications CS Mitsiades, N Mitsiades, V Poulaki, R Schlossman, M Akiyama, ... Oncogene 21 (37), 5673, 2002 | 628 | 2002 |
